problems, as well as family and social challenges. Matt spent many years as a teenager looking after his father as he progressed. After his father passed away in 2009, and as a result of his childhood experiences, Matt decided to dedicate his time to making a positive impact within the HD community and developed a keen interest in supporting young people affected by HD. Matt began his degree on Childhood and Youth in 2010, and started working on the creation of the Huntington's Disease Youth Organization (HDYO), a non-profit organization that provides support and education for young people affected by HD worldwide, shortly after. The idea for HDYO came after several trips to international HD conventions where there was an opportunity to hear other young people's experiences of HD. The lack of support and accessible educational resources was a common issue for young people. In 2011 Matt recruited a team of young volunteers to help create HDYO. The team created new educational content especially for young people, raised the funds needed to build a website, and registered HDYO as a non-profit organization. HDYO officially launched in February 2012; since then, the website has received 1.5 million page views, its educational content is regarded as some of the best for people of any age, the "team" now consists of over 100 volunteers, and HDYO is financially supported by almost all the HD associations around the world. interventions aimed at preventing or delaying disease onset. However, without robust and practical measures of disease progression (biomarkers) our ability to assess the efficacy of therapeutic interventions in this preHD population is limited. TRACK-HD was a multinational prospective observational study of HD that examined an extensive battery of clinical and biological biomarkers in control, preHD, and early-stage HD individuals. This presentation will review current progress in the development of potential biomarkers for disease progression in HD from the TRACK-HD study, and describe phenotypic changes in these participants over 36 months and identify baseline predictors of disease progression. Potential clinical, cognitive, neuroimaging, and biochemical biomarkers will be discussed in terms of their potential for widespread clinical application and utility in the development of future HD therapeutic trials. TRACK-HD, a rigorously controlled longitudinal study of the natural history of HD, has identified several potential biomarkers that are sensitive to change over 36 months in a preHD cohort. These findings from the TRACK-HD study improve our understanding of HD progression and will have important implications for clinical trial design in future preHD studies. Background: PREQUEL is the first multicenter interventional trial in pre-manifest Huntington's disease (HD). Objective : To assess the safety and tolerability of three different dosages of coenzyme Q 10 (CoQ) in patients with pre-manifest HD, and the feasibility of conducting therapeutic trials in this population. Methods: PREQUEL is a phase II randomized, doubleblind, multicenter trial of 600 mg, 1200 mg, and 2400 mg per day of CoQ. The 90 study participants were adults who had previously tested positive for the HD CAGn expansion (> 36 repeats) and who were deemed pre-manifest by having a diagnostic confidence score of ≤3 on the Unified Huntington's Disease Rating Scale (UHDRS). Tolerability was defined as the ability to complete the 20-week study on the originally randomized treatment assignment. A CoQ dosage was deemed tolerable if the observed tolerability was higher than a pre-specified threshold of 75 %. Results: The mean patient age was 39.5 years, 47 % were men, and 85 % were employed. The mean total UHDRS motor score was 3.5 and the mean estimated time to HD onset (Langbehn formula) was 11.5±11.1 years. PREQUEL had 93 % retention with 90 %, 93 %, and 84 % completing the trial on the originally assigned daily dosages of 600 mg, 1200 mg and 2400 mg of CoQ, respectively, all of which exceeded the pre-defined 75 % tolerability threshold. Compliance rates, based on pill counts, were 97 %, 95 %, and 96 %, respectively. There were 6 premature withdrawals, all felt to be unrelated to the study drug (4 occurring in patients on the 2400 mg/day dosage). The incidence of adverse events (45 %, 50 %, and 63 %, respectively) was not significantly different among the CoQ dosages; most were mild-to-moderate. CoQ levels increased in all dosage groups, and there was no significant difference among the three groups: mean ± SD of baseline levels were (in order of CoQ dosage) 0.77±0.30, 0.74±0.34, and 0.98±1.22 μg per ml, respectively, and 20-week levels were 2.55±1.82, 2.72±1.76, and 3.22±1.72. Recruitment at the 10 initial sites started rapidly but plateaued, and in order to fully enroll, the number of in-person visits was reduced, and 3 sites were added. Conclusion : CoQ was well tolerated at dosages up to 2400 mg/day for 20 weeks in patients with pre-manifest HD, with rates of study completion on the assigned dosage surpassing the pre-defined tolerability threshold in all treatment groups. The study shows the feasibility of conducting clinical trials in this population, but as most pre-manifest patients are actively employed, future studies should be designed to take this into account. *Previously presented at the Movement Disorders Conference on 19 June 2013 in Sydney, Australia.
10:20-10:45 AM KEYNOTE ADDRESS: Clinical Features of Pre-diagnosed Huntington's Disease Jane Paulsen, PhD, University of Iowa, Iowa City, IA, USA Introduction: Identifying early markers of Huntington's disease (HD) is important for clinical trials and clinical practice. We compared genetic, demographic, motor, cognitive, psychiatric, functional, and imaging measures in predicting conversion to manifest HD in a cohort of participants with the gene mutation. Methods: One thousand three hundred and fourteen participants at risk for HD were examined annually between 2001 and 2012. Linear mixed effects regression was used to examine clinical and imaging variables best suited for the detection of longitudinal change over time. Required sample sizes for a hypothetical randomized clinical trial were estimated for each possible outcome variable. A subset of 204 participants converted to manifest HD according to standard motor criteria, and analyses were conducted to examine predictors of diagnosis. Results: All 37 variables examined showed different rates of decline between premanifest HD and controls. Variables demonstrating the most robust differences included imaging, motor ratings, and cognitive performance, although significant changes were also detected for psychiatric and functional assessments. Joint modeling of the longitudinal markers and time to motor diagnosis showed that a 1 SD decline in putamen volume increased the risk of motor diagnosis 2.4 times, and a 1 SD increase in total motor impairments increased the risk 2.3 times. Conclusions: Preventive clinical trials in premanifest HD participants who have a medium or high probability of motor onset are calculated to be as cost effective as those conducted in diagnosed HD, and could interrupt disease 7-12 years earlier. Methods and measures for preventive clinical trials in premanifest HD far from motor onset are also feasible, should interventions prove ready for human trials. Among the 37 longitudinal markers examined, earlier diagnosis was associated with deterioration indexed by the markers. Apart from filling diagnostic roles, biological and refined clinical markers may also be utilized for prognosis, disease progression, development of new treatments, monitoring treatment effects, and for increasing the knowledge about pathologic processes coupled to the disease. Huntington's disease is a prototypic autosomal dominant disease; it is caused by CAG trinucleotide repeat expansion of the huntingtin gene. We take the approach that silencing the mutant huntingtin gene mRNA, thereby reducing production of the mutant huntingtin protein, is a logical therapeutic strategy. We advocate use of RNA interference to knock down mutant huntingtin messenger RNA, either by administration of potent small interfering RNAs or delivery by adenoassociated viruses that express small interfering RNAs. We study experimental alternatives that reduce the expression of mutant huntingtin messenger RNA by altering effectiveness of its translation and preventing its production by changing transcription. A combination of these efforts could provide long-and short-term treatment options to prevent neuronal dysfunction and premature death. Introduction and objectives: CAG repeat length is considered the most important determinant of age of onset for Huntington disease (HD). However, environmental factors may account for some of the remaining variability in age of onset and rate of disease progression. We aimed to explore the effects of alcohol and tobacco abuse as possible environmental risk factors for HD. Methods : We examined data collected in the Cooperative Huntington Observational Research Trial (COHORT, 2006 (COHORT, -2011 . The relationship between alcohol or tobacco abuse, and age of HD onset, was examined using multiple linear regression. We used the log-transformed age of onset as our outcome variable, given the known non-linear relationship between CAG repeat length and age of onset. CAG repeat length and gender were included as covariates on an a priori basis, and alcohol or tobacco abuse as test variables in model building. For disease progression, we carried out a similar analysis, quantifying disease progression as the rate of change in total functional capacity (TFC) score, between baseline visit and visit one. Results: Alcohol abuse was found to be associated with an earlier age of HD onset (n =954, p =0.0001), after adjusting for CAG repeat length and gender. In our model, a history of alcohol abuse brought forward the age of onset by 3.01 years in a man with 42 CAG repeats. No significant association was found between tobacco abuse and age of onset. Alcohol abuse was also found to be associated with a faster rate of decline in TFC (n =792, p =0.046), after adjusting for CAG repeat length and gender. Conclusions: Amongst the individuals of this large observational study, alcohol abuse was associated with an earlier onset of HD and faster disease progression. Avoidance of alcohol abuse may be beneficial for people carrying abnormal expansions in the HD gene. Since the advent of genetic testing for Huntington's disease in the mid-1980s, guidelines for testing published by both the Huntington Disease Society of America and the World Federation of Neurology prohibit the testing of people younger than the age of 18 years. Despite these guidelines, parents continue to request testing for children, and the average age of those coming for testing has been declining. Developmentally, this testing occurs at time of great social, emotional, and cognitive change. However, there is little research that has been done on the reasons why adolescents and young adults choose whether or not to get tested, and very little is known about subsequent coping and the impact on major life decisions. Research on narrative and psychotherapy suggests that creating a story to explain and understand past and current life concerns is associated with both physical and mental health benefits across diverse samples. This study uses the McAdams life story model to assess the content of 11 scenarios. Scenes are scored as to whether they depict a transformation from a bad, affectively negative scene, to a subsequent good, affectively positive scene (a redemptive sequence), or whether a good, affectively positive scene is transformed to a bad, affectively negative scene (a contamination sequence). Research shows that those employing redemptive framing score higher on indices of psychosocial adaptation. The specific aims for this project are 1) to examine whether redemption sequences found in life narratives correlate with higher scores for adjustment in a sample of adolescents and young adults at risk for HD; 2) to examine whether redemption/contamination sequences in life narratives are related to the decision whether or not to be tested for HD; and 3) to examine whether redemption sequences found in life narratives correlate with higher scores for adjustment after testing in a sample of adolescents and young adults at risk for HD. Thirty-six individuals at risk for HD between the ages of 14 and 29 years were interviewed either in person or by telephone. The average age of the participants was 23.75 years, with a range of 14-29 years. Twenty-seven had an affected mother, and 9 had an affected father. There were 28 females and 8 males. Sixteen had been tested or were in the process of testing, while 20 had not been tested. Results will be presented. Huntington's disease (HD) is a relentlessly progressive neurodegenerative disease for which no proven disease-modifying therapy currently exists. It is a complex disease, composed of 1) movement disorder; 2) cognitive impairment; 3) behavioural changes; and 4) genetic testing, which has serious implications for families. Current treatment efforts therefore focus principally on symptom alleviation, but there is currently no internationally accepted guidelines for the symptomatic management of this condition. Of note, there is also no dedicated HD clinic in the west of Ireland. It is estimated that 400-500 Irish people are affected, not inclusive of untested relatives. We therefore audited local practices of symptomatic therapy for our HD patients who attend our Movement Disorder Clinics. A retrospective audit was undertaken of patients with genetically confirmed HD attending the Movement Disorder Clinic at University Hospital Galway. Information on their 1) attendance record; 2) disease duration; 3) predominant symptomatology; 4) treatment regimens; 5) adherence and adverse reactions to therapy; and 6) non-drug therapies. This data was obtained from their inpatient charts. The information was collated and anonymised. On review of the literature, there are no peer-reviewed guidelines for the management of HD. Many medications are used, but only a minority of these are strongly proven to be of benefit. Other options have been investigated, such as deep brain stimulation, which helped chorea, but not disease progression, particularly in cognition. Thus, clinical judgement and experience dictate management worldwide. In our cohort, we found that every patient had different medication regimes and their opinions were not well documented. Similarly, there was scant documentation of community-based therapies. In future, we hope to 1) improve data quality by involving general practitioners; 2) develop a dedicated HD clinic; 3) improve communication with specialist nurse and HD-based societies; and 4) expand the database to possibly include other centres.
Poster 2
Severe Jaw Dystonia Causing Weight Loss in a Young Adult with Huntington's Disease Relieved by Tizanidine J. Mortimer, R. Zingales-Browne, C. Drazinic University of Connecticut Health Center, Farmington, CT, USA Introduction: Huntington's disease (HD) is a progressive, neurodegenerative disorder inherited in an autosomal dominant manner that is thought to affect up to 150,000 people in the USA, by conservative estimates. Children who inherited the mutation leading to HD through an affected father are at risk for an expansion of the trinucleotide repeat, causing an earlier onset of the disease. We are reporting a rare case of a 25-year-old man who developed symptoms of HD-related dystonia so severe that he could not swallow food, and, as a result, he experienced rapid 26.6-pound weight loss in a matter of months. Methods: In addition to changing the patient's diet to highcalorie soft foods, medications often used to treat dystonia, such as benztropine (Cogentin), were tried, without success. Owing to the patient's persisting jaw and neck dystonia, the alternative class of muscle relaxants were tried. Results: Tizanidine, a newer muscle relaxant that is an alpha-2 receptor agonist similar to clonidine, was tried in this patient, and the dystonia was resolved to the point that the patient was able to swallow again and now has only mild dysphagia. Of note, he regained some of the weight that he had lost previously, and his dystonia elsewhere in his body is minimal. Conclusions: Alpha-2 agonists may have a role in treating severe dystonia of advanced HD. Muscle relaxants may be considered in treating dystonia, in addition to spasticity. In the future, tizanidine treatment in other patients with dystonia from various causes, unresponsive to classical anticholinergic agents, will be explored.
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Statewide Collaboration between a Correctional System and a Huntington's Disease Clinical Program B. Hennig, R. Trestman University of Connecticut Health Center, Farmington, CT, USA Introduction: One of the impairments associated with Huntington's disease (HD) is disinhibition of behavior and risky decision-making. This can result in activity leading to incarceration. A major challenge is ongoing care coordination to optimize treatment, maintain community linkages during incarceration, and ensure successful community reintegration upon release. A model statewide program successfully addressing these challenges has been developed and implemented. Objectives: Describe the components of a statewide collaboration between a correctional system and a HD clinical program, the process of its implementation, and share illustrative case studies. Methods: The University of Connecticut Health Center (UCHC) hosts a statewide HD clinical program, responsible for providing care to people with HD, those atrisk for developing HD, and their families. The UCHC HD program has worked for several years with Correctional Managed Health Care (CMHC), a division of UCHC responsible for all healthcare for those incarcerated in Connecticut's jails and prisons. The UCHC HD program has developed active linkages for CMHC staff education, information sharing (especially regarding medication management), transport of patients to the clinic from custody for ongoing care consultation, and close coordination with CMHC Transition Managers for community re-entry planning. Results: UCHC HD patients who have become incarcerated have their care maintained without disruption are able to consult with their community-based care team, and the inevitable challenges of successful community re-entry are optimized with the shared skill sets and knowledge of 2 teams (correctional and community). Conclusion: Illegal, impulsive behavior of HD patients is not common. However, when it occurs it can seriously disrupt optimal care. The joint program developed in Connecticut may serve as a generalizable model to facilitate care continuity for HD patients who become incarcerated.
Poster 4 Can We Predict When Driving is No Longer Safe for People Who Have Huntington's Disease Using Standard Neuropsychological Measures?
B. Hennig, R. Kaplan, J. Berenguer University of Connecticut Health Center, Farmington, CT, USA Introduction: The cortex is involved early in HD and may contribute to deficits. Although there is a literature suggesting correlation between deficits in speed of processing, working memory, and executive function on driving competency, there is little direct evidence comparing these declines on laboratory tests to actual driving skills. Neuropsychological testing has been shown to be sensitive to mild cognitive impairment in attention, speed of processing, working memory, and executive functioning. The current case series examines the utility of specific neuropsychological measures in predicting actual driving competency. Participants and methods: Fifty-six patients from UConn HD Program underwent yearly evaluations. From a battery of 12 tests, 4 scales were chosen a priori to predict driving impairment. They included RBANS Coding Test, Trail Making Part B, Stroop Color-Word, and California Computerized Assessment Package (CalCAP). Patients were screened on the basis of TFC scores. Those scoring <7 were clinically impaired and required no further testing. Those with higher scores were tested. Results: Twenty-seven patients scored in the normal range. The remaining 29 patients scored below threshold suggestive of neuropsychological impairment. These 29 patients were found to have results on, the RBANS Coding Test, Trail Making Test Part B, Stroop Color-Word, and CalCAP reaction time within the impaired range (1.5. SD below age-corrected normative data). A referral to the Department of Motor Vehicles (DMV) for driving evaluation was subsequently made on these patients. Twenty-one of the 29 patients had their driving license suspended or voluntarily stopped driving. Five patients referred to DMV are pending a driving evaluation. The remaining 3 patients passed their driving evaluation. Conclusion: There is a correlation between scores on a battery of neuropsychiatric testing and driving competency. The relationship may provide information to guide more formal assessment of measures to reliably determine driving competence and the decision to refer to the DMV. (FY 2007 -FY 2011 : Based upon an analysis of adult HD claims, most allowances happen at the initial application. Out of total 4355 cases filed, 72.1 % were allowed at the initial level, 36.8 % were allowed at the reconsideration level, and 77.1 % were allowed after a hearing. Disability for HD and JHD (FY 2012 (FY -2013 : Since the HD code was implemented in 2012, there were a total of 268 HD and JHD cases in 2012, and 449 HD and JHD cases in 2013. The allowance rate at the initial level was 75.7 % in 2012 and 73.9 % in 2013. These rates may underestimate HD cases allowed because Disability Determination Services may still be using alternate codes. Discussion: As more progressive illnesses join the CAL list, a distinction will have to be made between conditions where a diagnosis with minimal objective medical evidence qualifies for fast track processing and disability benefits (JHD) and conditions where the individual must allege advanced symptoms and provide medical evidence (adult onset HD). Background: The Huntington's Disease Society of America (HDSA) the largest national voluntary health agency dedicated to improving the lives of people with Huntington's disease (HD) and their families, developed a set of resources to help educate caregivers about interactions with law enforcement, and to provide law enforcement and first responders with information about Huntington's disease to minimize negative encounters and increase mutual understanding. Objective: The HDSA created the Law Enforcement Toolkits in 2012 to give both caregivers and law enforcement the information they need to develop and maintain positive interactions. Each Toolkit contains educational materials for caregivers, as well as resources for law enforcement. To date, 330 people have ordered 674 copies of the Toolkits. A case study of one individual's experience using the HDSA Law Enforcement Toolkits in collaboration with local agencies illustrates how the HD community is using the Toolkits. Methodology: Lauren Holder, the president of the North Carolina Chapter, has been using the Toolkits with local police departments, as well as with the National Alliance of Mental Illness (NAMI) local Crisis Intervention Team (CIT) programs. CIT programs are local initiatives designed to improve the way law enforcement and the community respond to people experiencing mental health crises. To date, Lauren has had a dialogue with 4 NAMI affiliates, each of which operates on a county level. She is also corresponding with NAMI at the state level to discuss broader training. Results and conclusion: The HDSA Law Enforcement Toolkits have been helpful in 1) giving individuals in the HD community the tools they need to anticipate and potentially avert some interactions with law enforcement before they occur; 2) empowering members of the HD community to educate their local law enforcement; and 3) giving law enforcement and first responders up-to date, specific, targeted information about HD. In order to make early diagnosis of IT15 gene mutation in a Chinese Han Huntington disease (HD) families for providing them with genetic counseling and making preparation for the further research on pathogenesis and experimental therapy of HD, we collected peripheral blood samples and carried genetic diagnosis of pathogenic exon l of the IT15 gene by modified touchdown PCR and DNA sequencing methods from 12 pedigrees. Thirty-eight patient samples were analyzed. The CAG repeat numbers of the shorter allele were from 9 to 32. The numbers of the longer allele were from 34 to 81. More interestingly, a contraction was noticed in a maternal transmission, which changed the CAG repeat from an expanded, disease-causing allele (48 repeats) to a normal or intermediate allele (34 repeats). We further investigated the range of CAG repeats in normal Chinese populations from the mainland of China. We genotyped 35 unrelated normal Chinese controls, and subsequently sequenced the alleles with the smallest or largest PCR sizes. The CAG repeat numbers range from 8 to 25 in the normal Chinese populations. Only 2 individuals showed more than 20 CAG repeats, with (CAG)21 and (CAG)25, respectively. Additionally, according to our cooperation study, the CAG repeat number for 100 normal Caucasians of European descent from central Florida was found to be in the range of 8 to 35. Three individuals had a CAG repeat number >30 [(CAG)30, (CAG)32, and (CAG)35]. These observations suggest that Caucasians could have more individuals with intermediated sized non-pathologic alleles near the upper limit of the normal-sized range. These intermediatedsized non-pathologic alleles may act as a reservoir from which de novo mutations result in further expansion, leading to a much higher incidence of HD in Caucasians than in Asians. Background: Huntington's disease (HD), the most common autosomal dominant genetic disorder, is characterized by the progressive neuronal degeneration in the striatum and cortex, and associated functional impairments in motor, cognitive, and psychiatric domains. The disease is caused by abnormal expansion of polyglutamine repeat in huntingtin (Htt), a protein whose function is not yet fully known. Mutant Htt has detrimental effects on cell survival and on a number of neuronal cell functions, such as synaptic transmission, gene transcription, and production of neurotrophins. Recently, the expression of the mutant protein has been also associated with impaired metabolism of different lipid molecules, including sphingolipids, and therapeutic intervention at these levels may provide evidence to develop potential novel approaches for the treatment of the disease. FTY720, currently accepted for the treatment of multiple sclerosis, is a synthetic analogue of sphingosine, one of the major constituents of sphingolipids, cell membrane lipids including gangliosides. FTY720 crosses the blood-brain barrier and normally distributes to the brain where it exerts a number of protective effects on both neuronal and nonneuronal cells. Aim: In the present study we aimed to investigate whether FTY720 may exert beneficial effects also in HD and potentially identify it as alternative therapeutic approach for the treatment of the disease. Results: Chronic treatment with FTY720 resulted in improved motor function, prolonged survival, and reduced brain atrophy in R6/2 HD mouse model. Treatment benefits were associated with a significant strengthening of neuronal activity, increased levels of cortical and striatal brain-derived neurotrophic factor, and with a reduction of mutant Htt aggregates in HD mouse brain. Conclusion: This is the first evidence that strongly reports the preclinical validation of FTY720 as a neuroprotective agent in HD and supports FTY720 as a safe and useful molecule that could be advanced to human clinical trials for the treatment of the disease. Methods: Data from 865 HD gene-positive participants with complete cognitive/behavioral data and a clinical diagnosis of HD (UHDRS motor rating of 4) was extracted from the COHORT database. We analysed the data using Mann-Whitney U tests, correlation analyses, linear regression, and logistic regression. Regression analyses were adjusted for age, gender, education, cytosine-adenine-guanine (CAG) repeat length, and depression. Results: No significant differences were found between participants with and without behavioural symptoms at baseline in terms of either Stroop or MMSE performance. For participants with behavioural symptoms at baseline, only the MMSE, CAG, and depression were significantly associated with behavioural symptom severity. For participants without behavioural symptoms at baseline, depression and MMSE significantly predicted presence or absence of behavioural symptoms 12 months later. Conclusions: The Stroop composite score was not associated with behavioural symptoms in HD, but the MMSE was. The impact of depression on neuropsychological functioning, limitations of the Stroop test, and the disunity of behavioural symptoms in HD are discussed in terms of specific neuroanatomical correlates within the frontostriatal system. Huntington's disease (HD) is an autosomal dominant, neurodegenerative disease that has been investigated in several studies, including the Cooperative Huntington's Observational Research Trial (COHORT). One goal of COHORT is to estimate the risk of death associated with carrying a mutation in the causative HD gene using family history information from relatives of study participants. This work presents advanced and flexible statistical methods to estimate the risk of death while accounting for two main features in COHORT: 1) the relatives' genotype information and disease-risk is unknowninstead, relatives have an associated probability of being a mutation carrier or non-carrier; 2) the relatives' ages at death may be censored owing to patient drop-out or loss to follow-up. Our methods include three classes of new, asymptotically unbiased, and easily implementable estimators for estimating the risk of death. Among the new estimators, we show that the augmented inverse probability weighting estimator produces the most efficient estimates for risk of death without strict modeling assumptions. This is especially advantageous over current techniques, which we show have highly variable and biased estimates of risk of death. Extensive simulation experiments demonstrate satisfactory performance of our estimators, even when the data are heavily censored. When applying our estimators to COHORT, our analyses underscore an elevated risk of death in HD gene mutation carriers compared with noncarriers for a wide age range, and suggest that the mutation equally affects survival rates in both genders. Our estimates for the non-carrier group closely approximate the risk of death for the general US population, indicating small ascertainment bias in the COHORT family sample. Results from our work are useful in genetic counseling for providing guidelines on interpreting the risk of death associated with a positive genetic testing, and in facilitating individuals to make informed decisions on whether to undergo genetic mutation testing.
Poster 13 Successes and Sensitivities Using Three Mood Stabilizers to Treat Irritability in an HD Patient
T. Dujmovic, R. Zingales-Browne, C. Drazinic Huntington's Disease Program, University of Connecticut Health Center, Farmington, CT, USA Introduction: Irritability is a common hallmark of HD with prevalence ranging from 38 % to 73 %. While psychotropic medications are being used clinically, currently there is no officially approved medication for irritability management. Current guidelines suggest use of SSRI and antipsychotics as a first-line treatment of irritability. However, there is a limited evidence to support this, and larger-scale clinical trials are warranted. Objectives: To present successful management of the behavioral symptom of irritability in HD with mood stabilizers, with discussion of possible side effects. Methods: We describe the case of a 45-year-old Caucasian man with diagnosis of HD (CAG 46/17) who presented with significant irritability and anger outbursts. In providing medication treatment, mood stabilizers were utilized sequentially, including valproate, lithium, and, finally, carbamazepine, over the course of several months, based on the patient's response and tolerance of the medications. Results: While treatment with valproate (750 mg/daily) was successful in reducing irritability and anger outbursts, the patient developed a minor increase in liver function tests (LFTs) (aspartate transaminase = 103, alanine aminotransferase = 217), which was stable over 3 months. Given the patient's significant improvement in mood and behavior, the family was reluctant to have this medication stopped. Nevertheless, valproate was discontinued and LFTs normalized, but irritability re-emerged. Lithium was subsequently initiated to treat the patient's behavioral symptoms, but the patient developed sweating and shakiness from intermittent episodes of hypoglycemia (blood sugar~45), which had rarely been described previously in the literature. Therefore, the patient was switched to carbamazepine. Therapeutic blood levels were obtained (level = 8.8), and carbamazepine was successful in controlling the patient's irritability and mood swings. Conclusion: Mood stabilizers are potentially effective treatment of irritability in HD patients, but close monitoring for rare, potential side effects would be warranted for each of them, depending on what agent is utilized. . Gathering detailed food intake information while limiting patient burden is challenging. One large study in HD used the National Cancer Institute's Dietary History Questionnaire I paper version, requiring over an hour to complete, which was perceived as burdensome by researchers and patients. The FFQ provides pictorial guidance on food-serving sizes, can be taken from any web-enabled computer, and permits breaks as needed. Volunteers were recruited at the 2013 Huntington Disease Society of America conference. Sixty-seven people requested and received instructions for anonymously completing the FFQ. Participants took the FFQ either on-site or from home, and then responded to a 6-question post-survey probing their experience. Equal numbers took the survey on-site with study personnel present as took the survey at home. Thirty-four percent completed the FFQ; of those, 91 % completed the post-FFQ survey. Respondents selfreported their HD status: 45 % had manifest HD symptoms, 3 % were at risk for HD, 3 % were presymptomatic mutation positive, and 20 % had no known HD risk. Postsurvey responses were evaluated to determine the participant experience of the FFQ. Ninety percent reported that the FFQ was easy to understand, 85 % reported portion size pictures were helpful, 95 % reported foods queried reflected their actual diet, and 85 % would be likely to take a similar questionnaire again. The median time to complete the FFQ was 37.5 minutes. This study goal was to pilot nutrition data instrument not previously applied in HD populations. It was not powered to determine nutritional differences between HD, HD at-risk, and non-HD groups. These findings will inform decisions about implementing the online FFQ in larger nutrition intake studies in HD populations. Introduction: Individuals with basal ganglia disorders such as Huntington's disease (HD) and Parkinson's disease (PD) often exhibit gait disorders that are characterized by slower gait speed and greater than normal amounts of spatial and temporal strideto-stride variability. This retrospective study investigated the influence of walking speed on spatial and temporal stride-tostride variability in patients with HD and PD. Methods: Gait spatial and temporal measures obtained on adult patients with HD [mean age=51±13 years, mean Unified Huntington's Disease Rating Scale (UPDRS) motor score= 47.7±16.9 (range=1-86), n=138] and PD [mean age=68.8± 9.4, mean UPDRS motor score=25.6±9.5 (range=9-54), n =44] using the GAITRite system who attended the clinic between September 2008 and May 2011 were utilized. Only trials for which patients ambulated at both comfortable and fast walking speeds on the same clinic day were included. Coefficients of variability of step time, step and stride lengths, swing time, single support time, and double support time for each walk were calculated to determine gait variability. Comparisons between measures in comfortable and fast walking conditions for each patient population were analyzed using paired samples t-tests with post hoc Bonferroni corrections. Results: In the HD group, fast walking produced significant reductions (p <0.007) in step length, swing time, and single support time, and increased double-support time variability compared with comfortable walking. In the PD group, fast walking significantly reduced (p <0.002) stride length variability but did not affect any temporal gait variability measures. Implications: Fast walking reduced both spatial and temporal gait measure variability in individuals with HD, while reductions in spatial, but not temporal, gait measure variability were observed in individuals with PD. These findings suggest that individuals with HD might benefit from gait retraining strategies targeted to improve gait speed. Many people with adult onset Huntington's disease (HD) experience chorea. Chorea severity ranges from mild to disabling, but even mild chorea may impair basic daily functions or cause significant social embarrassment. Currently, tetrabenazine (TBZ) is the only Food and Drug Administration (FDA)-approved medication for symptomatic treatment of chorea associated with HD. TBZ is rapidly and extensively converted to active metabolites, which drive pharmacologic effect. These metabolites are, in turn, rapidly broken down by the enzyme CYP2D6. Limitations of TBZ include frequent dosing, short half-life, and high peak concentrations of active metabolites. These high peak concentrations may be associated with important side effects that limit usefulness. SD-809 is a novel, deuterium-containing form of TBZ, meaning deuterium replaces hydrogen at key places in the molecule, but SD-809 still has the same action in the brain as TBZ. The presence of deuterium slows the breakdown of the active metabolites. In healthy human volunteers, SD-809 had an increased half-life and smoother drug levels over time compared to TBZ, thus half the dose could achieve the same amount of drug in the body while avoiding the high peak concentrations seen with TBZ. The clinical trials First-HD and ARC-HD are evaluating the safety and effectiveness of SD-809 ER, a formulation of SD-809. First-HD is a double-blind, placebo-controlled trial testing if SD-809 ER reduces chorea in HD, and checking safety of SD-809 ER use. ARC-HD is an open-label study to assess the long-term safety of SD-809 ER. ARC-HD will enroll participants who successfully complete First-HD. ARC-HD will also enroll people already taking FDA-approved doses of TBZ for chorea in HD to help understand the safety of switching from TBZ to SD-809 ER. Overall, SD-809 has smoother blood levels and less frequent dosing than TBZ, with the potential to improve convenience, reduce side effects and reduce drug interactions. Background : A prominent pathological finding in Huntington's disease (HD) is accumulation of mutated huntingtin and progressive loss of medium spiny neurons (MSNs). PDE10A, highly enriched in MSNs of striatum, has an important role in regulation of cyclic adenosine monophosphate and cyclic guanosine monophosphate levels. Preclinical observations suggest PDE10A inhibitors may provide functional normalization of affected brain circuitry in HD. PDE10A inhibitors are in development as potential therapeutic targets for HD. The PDE10A tracer 18 F-MNI-659 provides a tool to investigate PDE10A expression in HD and evaluate drug occupancy for PDE10A candidate therapeutics. Methods: Patients with HD (n =7) and HV (n =9) were characterized with standard HD scales and completed 18 F-MNI-659 positron emission tomography (PET) imaging. Patients received 5 mCi (± 0. 5 mCi)
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18 F-MNI-659 and serial dynamic PET projection data was acquired over 1.5 h. Binding potentials (BPnd) were measured for caudate, putamen, globus pallidus, and striatum based on pharmacokinetic modeling using cerebellum as a reference region. Results: Mean age for HD 56.3 years (range, 31-67 years), and for HV it was 46.1 years (range, 29-71 years). HD patients had mild-to-moderate disease (HD stage 1-2) with means (range): Unified Huntington's Disease Rating Scale (UHDRS) total motor score 22.1 (4-44), UHDRS total chorea score 6.3 (0-12), total functional capacity 11.1 (9-13), and MMSE 28 (27-30).
18 F-MNI-659 mean BPnd for HD was significantly (p ≤0.001) lower than HC for each region: caudate HD 0.92, HV 2.03; putamen HD 1.67, HV 3.52; globus pallidus HD 1.84, HV 3.51; striatum HD 1.32, HV 2.79. Loss of expression appeared to be more pronounced in patients with higher motor scores. Conclusions : The PDE10A tracer 18 F-MNI-659 PET shows overall reduced binding in mild-to-moderate disease compared with HV with most pronounced reduction in the caudate, consistent with expected HD pathology. Ongoing studies will examine 18 F-MNI-659 PET imaging in pre-symptomatic gene-positive HD patients to further explore the change in PDE10A expression in HD. Background: PREQUEL is the first multicenter interventional trial in pre-manifest Huntington disease (HD). It is a safety and tolerability study evaluating the antioxidant coenzyme Q 10 (CoQ). Serum 8-OHdG, a potential biomarker of oxidative stress that is reportedly increased in pre-manifest HD was also measured in study participants. Objective: To compare mean serum levels of 8-OHdG in response to treatment with three different dosages of CoQ and to examine the association between 8-OHdG level and projected age of disease onset in patients with pre-manifest HD. Methods: PREQUEL is a phase II, 20-week, randomized, double-blind, multicenter trial of 600 mg, 1200 mg, and 2400 mg per day of CoQ. The 90 study participants were adults who had previously tested positive for the HD CAGn expansion (> 36 repeats) and who were deemed pre-manifest by having a diagnostic confidence score of ≤3 on the Unified Huntington's Disease Rating Scale (UHDRS). Subjects' serum levels of CoQ and 8-OHdG were measured at baseline and 20 weeks. An analysis was performed on these measurements in relation to CoQ dosage and predicted age of onset from CAGn repeat length (Langbehn formula).
Results: There was a significant increase in serum CoQ levels in all three treatment groups at 20 weeks. Levels (mean ± SD in μg/ml) of 8OHdG were (in order of CoQ dosage) 11.75± 3.99, 12.61±5.35, and 13.62±5.35 at baseline; and 11.94± 5.51, 11.49±4.63, and 13.73±7.14 at 20 weeks. There was no significant change in 8OHdG levels at 20 weeks for any dosage. There was no relationship between 8OHdG level at baseline and the predicted age of onset. Conclusion: Treatment with 600 mg/day, 1200 mg/day, and 2400 mg/day of CoQ was associated with increases in serum levels of CoQ, but with no change in 8OHdG levels. There was no relationship between 8OHdG level and predicted age of disease onset. These data call into question the utility of serum 8OHdG level as a biomarker of HD in the pre-manifest period and as a biomarker of response to the putative antioxidant CoQ. (HD) . No data exists on the feasibility of conducting the MoCA remotely in individuals with HD via telemedicine. Methods: Thirteen participants with HD enrolled in the study. Each participant completed a MoCA during a baseline in-person visit. Subsequent visits were conducted via telemedicine at approximately 1 month, 3 months, and 3.5 months from baseline. At the final visit the MoCA was conducted remotely via telemedicine. Feasibility was assessed by the ability to complete all items of the MoCA remotely. Intra-class coefficients (ICC) were calculated to determine the reliability of the MoCA conducted remotely compared with the in-person MoCA. Results: Ten participants completed the study. Two participants prematurely withdrew from the study prior to the completion of any telemedicine visits. Of the remaining participants, 9/10 (90 %) completed all items of the MoCA remotely. One participant declined to complete the final MoCA assessment remotely. The ICC between the remote and in-person MoCA was 0.66. Four (44.4 %) participants showed an increase (range, 2-6 points) and 2 participants had a decrease in MoCA (both 3 points) from in-person to remote assessment. Improved scores may be accredited to practice effects and/or improvements related to treatment effects over the course of the study whereas poorer scores may be accredited to progression of disease. Conclusion: Conducting the MoCA remotely in patients with HD is feasible and reliable. Differences between in-person and remote scores may represent a combination of differences in administration, practice effects and/or disease progression. The ability to conduct cognitive assessments remotely may assist in the longitudinal follow up of individuals with HD for care and research. This research was funded by a research grant from Lundbeck Inc., Deerfield, IL, USA. PBT2 is a metal-protein attenuating compound that has demonstrated promise in an early stage Alzheimer's disease clinical trial, but has not been previously evaluated in HD. Objective: To evaluate the safety and tolerability of 2 doses of PBT2 in individuals with early-to-mid-stage HD. Methods: We conducted a 6-month randomized, doubleblind, placebo-controlled study of 2 doses of PBT2 in individuals with early-to-mid-stage HD. Individuals with a total functional capacity of 6-13 inclusive and a score of at least 12 on the Montreal Cognitive Assessment were randomized, 1:1:1 to 100 mg once daily PBT2, 250 mg once daily PBT2, or matching placebo. Safety measures included assessments of adverse events, neurological, neuropsychiatric and ophthalmological batteries, vital signs, clinical laboratory tests, electrocardiograms, and visual evoked responses in a subset of participants. Tolerability was assessed by the ability of study participants to complete the study on the assigned dosage. Secondary assessments included cognitive, motor, behavior, and functional outcomes, and blood, urine and neuro-imaging biomarkers. Results: The study enrolled 109 participants at 19 research centers in Australia (n =5) and the USA (n =14). Of the 109 participants, 104 (95 %) completed the study. The primary and secondary outcomes of the study are under review and analysis currently. Conclusion : The Reach2HD study has been successfully completed. The results should inform the safety and tolerability of PBT2 and the clinical pathway forward for PBT2 as a potential treatment for individuals with HD. Sponsor: Prana Biotechnology Limited.
A pilot project was undertaken to increase awareness in a large southeastern state lacking a formal Center of Excellence. The state of North Carolina (NC) has a 72 % rural/28 % urban population exceeding 9 million people. The project leveraged an international HD event (HSG 2013 annual meeting) to target specific populations within NC. Press releases and media materials were developed based on interviews with HD experts and advocates, and distributed to proprietary media and HD-specific databases in the 6 months prior to the HSG meeting. At the halfway point in the project, analytics indicate broad readership. Cumulative press release delivery to date is 128,795 with a minimum readership rate of 18.5 %, or 23,777. Approximately 60 % readership is within NC. Readership penetrated 50 US states, DC, Puerto Rico and 41 nations. Nine hundred and ninety-five media pickups (use of press material by media, social media, website postings, and RSS feeds) have been detected. Exposure is likely under-represented as forwarding of emails and media material cannot be assessed. The rate of requests for information, care, consultation, and subject enrollment in clinical trials will be tracked in the year following the campaign to evaluate long term impact. A traditional marketing campaign to increase awareness of HD in a defined geographic area served to engage a broad readership in the media, general population, family community, and healthcare industry. Refinement of marketing techniques and enhanced understanding of their impact may increase disease awareness and improve access to needed health care resources for isolated families. This studied examined trauma symptomatology and heart rate variability in patients with Huntington's disease (HD). Patients of the University of California, Los Angeles Neurology Clinic (n = 59) were divided into 3 groups (presymptomatic, early symptomatic, and manifest HD) and asked to complete the TSI-II, DES-II and the WHOQOL-100. Physiology was recorded using J&J Engineering's I-330-C2+ 12 Channel biofeedback equipment. Hypotheses stated that patients would report more trauma symptoms and dissociative experiences in the later stages of the disease, which would also predict their QOL; HD patients who exhibited more dissociative behaviors would report less trauma symptoms. It was also hypothesized that a HD patient's physiological reactivity would correlate with TSI and DES-II scores. Results suggest that HD patients do, in fact, experience trauma symptoms above normal ranges and report higher levels in the later stages. Dissociation, daily functioning, and trauma all significantly predicted higher QOL scores. Physiology correlated with depression and suicide, but not trauma and dissociation.
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respectively. Motor symptoms were most often reported as the most bothersome problem. Severity of the most, second, and third bothersome problems, rated on a scale of 1-4, followed a linear trend: the problem reported as most bothersome was also rated as more severe (p =0.0075). Overall, "functional" problems were rated the most severe and "motor" problems were rated the least severe. Conclusion : Although "motor" problems were most frequently reported, this overview of the HD-PROP dataset highlights the importance of "functional" problems in clinical practice and research. "Functional" problems are rated as most severe by patients and can be due to a combination of impairments. The HD-PROP is useful for assessing PROs from HD patients in a clinical trial. This research was supported by Prana Biotechnology, Melbourne, Australia. Introduction: Cognitive symptoms in Huntington's disease (HD) are characterized by progressive changes in cognitive and decision-making ability. We investigated how risk-based decision-making strategies are altered following rewarded feedback in HD patients. Design: All 17 HD and 15 healthy control (HC) participants completed a risk-taking task in which they made a series of choices between more certain but low reward and less certain but high reward risk options. We measured group differences in overall risk preference as well as differences in how the groups adjusted their risk strategy after risk decisions were either rewarded or unrewarded. Mean age was similar for both groups [HD (48.7) vs HC (43.3)]. HD patients had a mean Unified Huntington's Disease Rating Scale score of 35.64 and disease duration of 2.18 years. Results: HC showed a clear preference for low risk (62 %) compared to high-risk (38 %) decisions, whereas the HD group showed equal preference for low-(49 %) and high-risk (51 %) decisions. When a high-risk decision was rewarded, HC adopted a more conservative risk strategy on the next trial (i.e., preferred the low-risk option on 67 %), but HD showed a preference for repeating the high-risk decision (55 %). Conclusion: In this study, we show that compared to HC, HD patients tend to 1) prefer high-risk choices and 2) persist with high-risk choices if they are rewarded. This suggests that rewarding feedback differentially effects cognitive decisionmaking in HD. Previous studies of risk-taking emphasize that individual differences in frontal-striatal function influence the likelihood of choosing a high-risk option subsequent to a rewarded high-risk choice. These data suggest that alterations to limbic frontal-basal ganglia function may differentially influence risk-taking HD patients. Future work will characterize network differences that account for this behavioral finding. The most frequent point of medical care for Huntington's disease (HD) occurs in general medical offices by physicians who have had few hours of HD training. Providing education via targeted outreach can improve HD medical care and enable people with or at risk for HD to receive communitybased quality care. In one effort to address this education gap, the Huntington Study Group and LaVonne Goodman from the Northwest (NW) Chapter of the Huntington's Disease Society of America developed and presented a CME course designed to provide up-to-date HD diagnostic, treatment and management training for primary care and specialty physicians and other health providers. Funded by the Griffin Foundation, the course was offered concurrently with the 2012 annual Huntington Study Group Clinical Research Symposium. Forty-one providers, including neurologists, general medical physicians, nurses, long-term care administrators, social workers, and genetic counselors attended all or part of the 13.5 accredited hours. Subsequently, in a cooperative effort of the NW Chapter and the University of Washington Center of Excellence (COE), we are using CME-accredited course materials to present training sessions in the facilities of local providers and long-term care facilities. This course includes information on support and medical services through the COE and NW Chapter, describes behavioral and motor symptoms, discusses interventions, and includes information about local research studies and trials. By offering local provider access to HD consultative, education, and support services, we hope to identify and recruit community-based medical providers willing and better trained to care for patients with HD. When new providers are identified, contact information is supplied to the patient and family community through Chapter web blasts and help-line requests.
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Outcomes of types and numbers of new providers and institutions gained through this project will be presented, and a cost analysis will be described for this low technology model of outreach care. 
